Bio Legend (LEGN) Stock: CARVYKTI Drives 66% Q4 Sales Surge and 2026 Profitability Outlook

TLDR

• CARVYKTI Q4 net trade sales hit $555M, rising 66% year over year globally.
• U.S. sales reached $420M while international revenue tripled to $135M.
• Manufacturing capacity targets 20,000 doses with strong 97–99% success rates.
• Clinical data shows 50.4-month progression-free survival in key patients.
• Legend Biotech expects enterprise-wide profitability by 2026.

Legend Biotech (LEGN) stock fell 1.77% to $18.80 as CARVYKTI continued strong global sales momentum. The company reported $555 million in net trade sales for Q4, a 66% year-over-year increase. CARVYKTI reached profitability in 2025, and enterprise-wide profitability is expected in 2026, supporting Bio Legend stock’s long-term outlook.

Legend Biotech Corporation, LEGN

CARVYKTI Sales Growth and Market Expansion

CARVYKTI net trade sales totaled $420 million in the U.S., rising 38% year-over-year and 6% sequentially. International sales reached $135 million, more than tripling from the prior year period, supported by Germany, Spain and Belgium. Bio Legend stock benefits from 14 global markets and 294 treatment sites expanding CARVYKTI’s footprint worldwide.

The company installed manufacturing capacity for 10,000 doses and plans to increase capacity to 20,000 with Johnson & Johnson. CARVYKTI manufacturing success rates ranged from 97% to 99%, ensuring reliable global supply. These manufacturing metrics support both growing demand and a favorable outlook for Bio Legend stock.

CARVYKTI usage increasingly occurs earlier in treatment, with 65% of patients now receiving therapy in the second-to-fourth-line setting. Spain showed 70% to 75% early-line treatment adoption, reflecting broader international trends. This earlier use could strengthen clinical outcomes and drive sustained CARVYKTI sales growth.

Clinical Data and Patient Management Updates

Long-term data from CARTITUDE-1 and CARTITUDE-4 showed a median progression-free survival of 50.4 months in triple-class-exposed patients. Standard-risk patients remained 80% progression-free after 2.5 years, with 93% alive and off treatment if progression-free at one year. These results reinforce CARVYKTI’s durability and support Bio Legend stock through demonstrated clinical value.

Patient management strategies now emphasize bridging therapies to reduce tumor burden and mitigate neurotoxicity. Studies show no colitis or Parkinsonism in patients who received bridging therapy before CARVYKTI infusion. Ongoing research and updated NCCN guidance further optimize patient safety and treatment effectiveness.

Bio Legend also presented Lucar-G39D data, an allogeneic CAR T-cell therapy for relapsed or refractory B-cell non-Hodgkin’s lymphoma. Early results indicated manageable safety and encouraging antitumor activity. Expanding the pipeline beyond CARVYKTI positions Bio Legend stock for diversified growth potential.

Financial Results and Profitability Outlook

Legend Biotech reported $306 million in fourth-quarter revenue, up 64% year-over-year, with a gross margin of 61%. Operating loss improved to approximately $20 million, and adjusted net income was $2.5 million compared with a prior-year loss of $59 million. Bio Legend stock is supported by a clear path to enterprise-wide profitability in 2026.

R&D spending decreased 3% as BCMA frontline programs matured, while SG&A rose 22% due to commercial investments. Cash, cash equivalents, and time deposits totaled $949 million at year-end, with operating cash flow outlays of $12 million in Q4. Sequential quarterly growth and planned manufacturing expansions underpin Bio Legend stock’s strategic outlook.

Management projects roughly 50% top-line CARVYKTI growth in 2026, driven by global adoption and site expansion. In vivo CAR T development and non-viral delivery exploration complement existing oncology and hematology programs. Overall, Bio Legend stock performance aligns with robust sales, clinical durability, and a growing global footprint.

The post Bio Legend (LEGN) Stock: CARVYKTI Drives 66% Q4 Sales Surge and 2026 Profitability Outlook appeared first on CoinCentral.